title: Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests.
abstract: Causative agent in majority of VVC is Candida albicans, but infection due to non-C. albicans is common. Use of empiric antifungal therapy in Brazil due to syndromic management of vulvovaginitis could act as risk factor for increase resistance among VVC causative agents. From Mato Grosso patients, 160 with culture-proved among 404 women who had clinical symptoms of VVC, were enrolled in this study. 70 non-pregnant women and 90 pregnant women were included. Candida albicans was the most prevalent, representing 72.9% in the non-pregnant group and 92.3% in the pregnant group. Differences in species distribution were noted between the two groups, being C. parapsilosis the second more prevalent species among non-pregnant women. Susceptibility testing revealed high susceptibility to fluconazole (except for C. krusei), itraconazole, ketoconazole, and amphotericin B regardless the species (C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, C. krusei) analyzed.
authors.affiliation: Faculdade de Ciências Médicas, Universidade Federal de Mato Grosso , Cuiabá, MT , Brasil.
authors.forename: Luciana Basili
authors.initials: LB
authors.lastname: Dias
authors.forename: Márcia
authors.initials: M
authors.lastname: de Souza Carvalho Melhem
authors.forename: Maria Walderez
authors.initials: MW
authors.lastname: Szeszs
authors.forename: José Meirelles
authors.initials: JM
authors.lastname: Filho
authors.forename: Rosane Christine
authors.initials: RC
authors.lastname: Hahn
keywords: Candida albicans; Vulvovaginal candidiasis; antifungal agents; antifungal susceptibility testing
references.citation: J Clin Microbiol. 2005 May;43(5):2155-62
references.pmid: 15872235
references.citation: Mycoses. 2009 Jan;52(1):24-8
references.pmid: 18498300
references.citation: East Afr Med J. 2005 May;82(5):226-34
references.pmid: 16119751
references.citation: Eur J Epidemiol. 1997 Jun;13(4):447-50
references.pmid: 9258552
references.citation: Diagn Microbiol Infect Dis. 2004 Mar;48(3):153-60
references.pmid: 15023422
references.citation: Med Mycol. 2005 Nov;43(7):647-50
references.pmid: 16396250
references.citation: Lancet. 2007 Jun 9;369(9577):1961-71
references.pmid: 17560449
references.citation: Mycoses. 2006 Nov;49(6):471-5
references.pmid: 17022763
references.citation: Arch Gynecol Obstet. 2008 Aug;278(2):173-6
references.pmid: 18214512
references.citation: Mycoses. 2007 Jan;50(1):13-20
references.pmid: 17302742
references.citation: Int J STD AIDS. 2000 Aug;11(8):516-20
references.pmid: 10990336
references.citation: Rev Argent Microbiol. 2006 Jan-Mar;38(1):9-12
references.pmid: 16784126
references.citation: Scand J Infect Dis. 2006;38(1):49-54
references.pmid: 16338838
references.citation: Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):211-5
references.pmid: 16054964
references.citation: Clin Microbiol Infect. 2005 Dec;11(12):1005-11
references.pmid: 16307555
references.citation: Antimicrob Agents Chemother. 1990 May;34(5):909-10
references.pmid: 2360828
references.citation: Antimicrob Agents Chemother. 2003 Jan;47(1):34-8
references.pmid: 12499165
references.citation: Rev Iberoam Micol. 2004 Dec;21(4):202-5
references.pmid: 15709802
references.citation: Medscape Womens Health. 1997 Feb;2(2):2
references.pmid: 9746676
references.citation: Infect Genet Evol. 2007 Jul;7(4):449-56
references.pmid: 17324639
references.citation: Obstet Gynecol. 2002 Mar;99(3):419-25
references.pmid: 11864668
references.citation: Am J Obstet Gynecol. 1998 Feb;178(2):203-11
references.pmid: 9500475